Clinical trials: pills and oral medicines
Kidney Transplant
Dosing Strategies for de Novo Once-daily Extended Release Tacrolimus (LCPT) in Kidney Transplant Recipients
Outcomes after kidney transplantation have been significantly enhanced with the advances made in immunosuppressive therapies. Tacrolimus is currently marketed as an extended-release once-daily formulation dosing option for…
- Trial name
- NCT03713645
- Testing
- Tacrolimus Extended Release Oral Tablet [Envarsus] 0.13mg/kg/day initiated within post-operative day 3 after kidney transplant
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Temple University
Chronic Kidney Disease
A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and Allopurinol
This study is a single centre, randomised, open-label, single-dose, 5-period, 5-treatment, crossover study in healthy male and female subjects.
- Trial name
- NCT04550234
- Testing
- Verinurad prolonged release HPMC capsule, Allopurinol Tablet, Verinurad/Allopurinol FDC Capsule
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Hand Dermatitis
Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema
Randomized double-blind/placebo study to evaluate the efficacy of ASN002 in subjects with severe chronic hand eczema.
- Trial name
- NCT03728504
- Testing
- ASN002
- Where
- 23 sites in United States, Canada
- Volunteers
- 97 people
- Sponsor
- Asana BioSciences
Celiac Disease, Coeliac Disease
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and to Evaluate the Interaction Between GSK3915393 and Grapefruit Juice and Itraconazole
This is a 3-part first time into human study (FTIH) study for GSK3915393. Parts A and B of the study will evaluate the safety, tolerability and pharmacokinetics (PK) of single ascending and repeat oral doses of GSK3915393 in…
- Trial name
- NCT04604795
- Testing
- GSK3915393 Capsules, GSK3915393 Solution for Infusion, Itraconazole
- Where
- United Kingdom
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Parkinson Disease
Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole
Subjects stable on L-Dopa and oral ropinirole will have their ropinirole replaced with the Ropinirole Implant(s). The Ropinirole Implant was designed using the ProNeura™ implant technology where the implant is inserted under the…
- Trial name
- NCT03250117
- Testing
- Ropinirole oral product, Ropinirole Implant
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Titan Pharmaceuticals
Hormone Receptor Positive Breast Cancer
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer
The purpose of this study was to assess the efficacy and safety of first-line treatment with everolimus plus letrozole in postmenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2…
- Trial name
- BOLERO-4 (NCT01698918)
- Testing
- Everolimus, Letrozole, Exemestane
- Where
- 52 sites in United States, Argentina and 11 more
- Volunteers
- 202 people
- Sponsor
- Novartis Pharmaceuticals
Progressive Multiple Sclerosis
A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis
This study aims to identify the safety and tolerability of bile acid supplementation in patients with progressive Multiple Sclerosis (MS).
- Trial name
- NCT03423121
- Testing
- Tauroursodeoxycholic Acid
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Johns Hopkins University
Drug Drug Interaction
Drug-drug Interaction (DDI) Study of Spironolactone (Perpetrator) and Digoxin (Substrate Drug)
An open label, balanced, randomized, single-dose, two-treatment, two-sequence, two-period, crossover oral drug-drug interaction study of spironolactone (perpetrator) and Digoxin (substrate drug) in healthy adult human subjects…
- Trial name
- NCT03909529
- Testing
- Digoxin 250 MCG Oral Tablet, Spironolactone 25 mg/ 5 mL S/F Suspension
- Where
- India
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- CMP Development, LLC
Negative Symptoms of Schizophrenia
Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia
MIN-101C07 is a multicenter, multinational, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of roluperidone in adult schizophrenia patients.The primary objective is to…
- Trial name
- NCT03397134
- Testing
- Roluperidone 32 mg, Roluperidone 64 mg
- Where
- 39 sites in United States, Bulgaria and 2 more
- Volunteers
- 515 people
- Sponsor
- Minerva Neurosciences
Alcohol Use Disorder (AUD)
Medication Development in Alcoholism: Suvorexant Versus Placebo
The primary hypotheses under test are that alcohol dependent subjects treated with suvorexant will report decreased craving for alcohol following alcohol exposure in the laboratory and report significantly less drinking under…
- Trial name
- NCT04229095
- Testing
- Suvorexant 20 mg
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- The Scripps Research Institute
Traumatic Brain Injury, Headaches Posttraumatic
Adjunct VR Pain Management in Acute Brain Injury
Severe and refractory pain after acute injury is a known-risk factor for chronic opioid use disorder. In this study, the investigators will use Virtual Reality (VR) immersion as a non-pharmacological adjunct to treat pain…
- Conditions
- Traumatic Brain Injury, Headaches Posttraumatic, Trauma, Pain, Acute
- Trial name
- NCT04356963
- Testing
- Virtual Reality Session (VR Blu), Tablet-based Session (Tablet Blu), Use of Virtual Reality Head Mounted Display without Content (VR Blank)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Maryland, Baltimore
COVID-19 Pneumonia, Vascular Complications
Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19
Brief Summary: The goal here is to evaluate dipyridamole in treating respiratory tract infection and circulatory dysfunction due to SARS-CoV-2 coronavirus in hospitalized CVID-19 patients.
- Trial name
- TOLD (NCT04424901)
- Testing
- Dipyridamole Tablets
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- UConn Health
Asthma, Vitamin D Deficiency
Vitamin D Oral Replacement in Asthma
The overall objective of the study is to determine the pharmacokinetics of Vitamin D supplementation in children who have asthma and are overweight or obese.
- Conditions
- Asthma, Vitamin D Deficiency, Pediatric Obesity
- Trial name
- VDORA1 (NCT03686150)
- Testing
- Vitamin D3 oral regimen
- Where
- 15 sites in United States
- Volunteers
- 112 people
- Sponsor
- IDeA States Pediatric Clinical Trials Network
Poliomyelitis
A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age
The purpose of this study is to assess the safety (serious adverse events [SAEs]), and severe adverse events [AEs] (grade 3 according to CTCAE 4.03) after one dose of SABIN tOPV in 1-5 year-old children and three doses of SABIN…
- Trial name
- T2-ABMG (NCT02580201)
- Testing
- Oral Polio Vaccine
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Fidec Corporation
Psoriasis
Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis
This study evaluates the treatment of psoriasis with aminopterin. Participants will be treated for 14 weeks with either aminopterin or placebo followed.
- Trial name
- NCT03431974
- Testing
- LD-Aminopterin oral capsule
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Syntrix Biosystems, Inc.
Pediatric Crohn's Disease
Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
The purpose of this study is to determine whether adding low dose methotrexate to anti -TNF therapy is more effective than treatment with anti-TNF therapy alone in inducing and maintaining steroid-free remission for children with…
- Trial name
- COMBINE (NCT02772965)
- Testing
- Methotrexate
- Where
- 32 sites in United States
- Volunteers
- 306 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV/AIDS
Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI Tract
Purpose: To Assess the impact of high and low in vivo estradiol exposure on PrEP (Pre-exposure prophylaxis) nucleotide concentrations in different cellular populations of the lower GI (gastrointestinal) tract and to quantify the…
- Trial name
- NCT03917420
- Testing
- Tenofovir 300Mg Oral Tablet, Emtricitabine 200 MG
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Parkinson Disease
Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease
This study is a placebo-controlled, double-blind trial that will investigate the safety and tolerability of molecular hydrogen, a promising antioxidant agent, in patients with early-stage Parkinson's Disease.
- Trial name
- NCT03971617
- Testing
- Hydrogen
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Stony Brook University
Opioid Dependency
Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED)
This is a multi-center, open-label, preference study of two sublingual formulations of buprenorphine HCl, in opioid-dependent patients on buprenorphine maintenance therapy.
- Trial name
- NCT01075971
- Testing
- Buprenorphine hydrochloride marketed sublingual tablet (Subutex), Buprenorphine hydrochloride fast dissolving tablet (FDT)
- Volunteers
- 52 people
- Sponsor
- Indivior Inc.
Sialorrhoea
A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease
The purpose of this study is to determine whether OC (oxybutynin and clonidine) oral solution is effective in reducing saliva secretion in patients suffering from Parkinson's Disease with excessive salivation.
- Trial name
- NCT01370811
- Testing
- oxybutynin and clonidine oral solution treatment A, oxybutynin and clonidine oral solution treatment B, oxybutynin and clonidine oral solution treatment C
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Orient Pharma Co., Ltd.